Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in an adjuvant melanoma study.

It is the second agreement in the ADC category for BMS in the last few weeks, coming after a smaller $180 million partnership with Orum Therapeutics on an ADC in the protein degrader class with ...

A high-level overview of Bristol-Myers Squibb Company (BMY) stock. View (BMY) real-time stock price, chart, news, analysis, analyst reviews and more.